zibotentan (ZD4054) / University of Virginia, AstraZeneca, Royal Papworth Hospital  >>  Phase 2
Welcome,         Profile    Billing    Logout  

8 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zibotentan (ZD4054) / AstraZeneca
ZENITH-CKD, NCT04724837 / 2020-004101-32: Zibotentan and Dapagliflozin for the Treatment of CKD ( Trial)

Completed
2b
542
Europe, Canada, Japan, US, RoW
Zibotentan, Dapagliflozin, Placebo
AstraZeneca, AstraZeneca AB
Chronic Kidney Disease
06/23
06/23
2008-002686-30: Assessment of the effects of the specific endothelin-A antagonist ZD4054 on prostate cancer biomarkers in patients with castrate-resistant metastatic disease

Ongoing
2
30
Europe
ZD4054,
Christie Hospital NHS Foundation Trust
Prostate cancer
 
 
2018-004393-10: Precision medicine with zibotentan in microvascular angina (PRIZE)

Not yet recruiting
2
356
Europe
Zibotentan, ZD4054, Tablet
NHS Greater Glasgow & Clyde, University of Glasgow, Medical Research Council, AstraZeneca UK Ltd
Microvascular Angina and impaired exercise intolerance., Microvascular angina refers to disease in the small blood vessels, associated with both a reduced quality of life and often-repeated acute hospital admissions or long-term clinic attendance, Diseases [C] - Cardiovascular Diseases [C14]
 
 
2021-001324-18: A Study to Assess the Effects of the drugs Zibotentan and Dapagliflozin in Patients with Elevated Levels of Protein in Urine

Not yet recruiting
2
38
Europe
zibotentan, Dapagliflozin, ZD4054, Dapagliflozin, Capsule, hard, Tablet, Forxiga
University Medical Center Groningen, Astra Zeneca
Patients with elevated Albuminuria, Patients with protein in the urine, Diseases [C] - Hormonal diseases [C19]
 
 
PRIZE, NCT04097314: Precision Medicine With Zibotentan in Microvascular Angina

Completed
2
225
Europe
Zibotentan, Placebo oral tablet
NHS Greater Glasgow and Clyde, University of Glasgow, King's College London, University of Oxford, Oxford University Hospitals NHS Trust, University of Cambridge, Papworth Hospital NHS Foundation Trust, Blackpool Teaching Hospitals NHS Foundation Trust, Royal Free Hospital NHS Foundation Trust, AstraZeneca UK Ltd, Siemens Healthcare Ltd
Microvascular Angina
06/23
06/23
ZEAL UNLOCK, NCT06269484: A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK

Recruiting
2
66
Europe, Japan, US, RoW
Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin
AstraZeneca
Liver Cirrhosis
01/25
01/25
ZODIAC, NCT05570305: Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

Enrolling by invitation
2
38
Europe, Canada, US
Zibotentan, Dapagliflozin, Placebo, Dapagliflozin and Zibotentan
University Medical Center Groningen, AstraZeneca
Chronic Kidney Diseases
04/24
09/24
ZEAL, NCT05516498 / 2021-006577-30: Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis ( Study)

Recruiting
2
195
Europe, Canada, US, RoW
Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part A: zibotentan (dose B) + dapagliflozin, Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part B: placebo (matching zibotentan capsule) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin, Part B: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose C) + dapagliflozin
AstraZeneca, AstraZeneca AB
Liver Cirrhosis
01/25
04/25

Download Options